See more : M3-Brigade Acquisition V Corp. Units (MBAVU) Income Statement Analysis – Financial Results
Complete financial analysis of Ipsen S.A. (IPSEY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ipsen S.A., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Lexicon Pharmaceuticals, Inc. (LXRX) Income Statement Analysis – Financial Results
- Rockridge Resources Ltd. (ROCK.V) Income Statement Analysis – Financial Results
- Aena S.M.E., S.A. (AENA.MC) Income Statement Analysis – Financial Results
- RDB Rasayans Limited (RDBRL.BO) Income Statement Analysis – Financial Results
- Aspen Pharmacare Holdings Limited (APNHF) Income Statement Analysis – Financial Results
Ipsen S.A. (IPSEY)
About Ipsen S.A.
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.31B | 3.16B | 3.00B | 2.69B | 2.69B | 2.35B | 2.01B | 1.67B | 1.52B | 1.33B | 1.28B | 1.28B | 1.23B | 1.17B | 1.11B | 1.04B | 993.76M | 861.68M | 788.71M | 723.99M |
| Cost of Revenue | 571.20M | 527.70M | 538.00M | 490.60M | 488.00M | 454.20M | 385.60M | 353.30M | 336.80M | 310.00M | 253.39M | 254.77M | 249.24M | 236.19M | 237.81M | 219.93M | 199.03M | 181.38M | 176.83M | 176.31M |
| Gross Profit | 2.74B | 2.63B | 2.46B | 2.20B | 2.20B | 1.89B | 1.63B | 1.32B | 1.18B | 1.02B | 1.03B | 1.02B | 985.67M | 934.11M | 874.58M | 818.18M | 794.73M | 680.30M | 611.88M | 547.68M |
| Gross Profit Ratio | 82.72% | 83.28% | 82.06% | 81.74% | 81.88% | 80.66% | 80.83% | 78.86% | 77.85% | 76.73% | 80.23% | 80.06% | 79.82% | 79.82% | 78.62% | 78.81% | 79.97% | 78.95% | 77.58% | 75.65% |
| Research & Development | 619.30M | 445.30M | 428.40M | 405.60M | 388.80M | 302.10M | 265.80M | 208.90M | 192.60M | 186.90M | 259.05M | 248.55M | 253.59M | 221.13M | 197.29M | 182.92M | 184.74M | 178.35M | 167.57M | 140.79M |
| General & Administrative | 217.80M | 205.80M | 199.60M | 187.80M | 181.40M | 165.70M | 140.80M | 129.40M | 122.90M | 111.20M | 103.82M | 99.09M | 101.47M | 98.25M | 88.46M | 85.90M | 80.43M | -232.58M | -225.80M | -318.06M |
| Selling & Marketing | 917.10M | 833.40M | 835.70M | 784.00M | 838.60M | 787.40M | 715.90M | 608.40M | 541.40M | 464.10M | 451.27M | 473.48M | 425.15M | 422.81M | 396.14M | 358.40M | 321.05M | 307.80M | 292.59M | 319.24M |
| SG&A | 1.13B | 1.04B | 1.04B | 971.80M | 1.02B | 953.10M | 856.70M | 737.80M | 664.30M | 575.30M | 555.09M | 572.57M | 526.62M | 521.06M | 484.61M | 444.30M | 401.48M | 75.22M | 66.79M | 1.18M |
| Other Expenses | 165.00M | 273.00M | 119.10M | 97.70M | 132.90M | 82.70M | 102.40M | -21.70M | -7.20M | -9.20M | -6.26M | -20.21M | 7.92M | 12.76M | -3.47M | -677.00K | 17.41M | -12.62M | -2.62M | -1.58M |
| Operating Expenses | 1.92B | 1.76B | 1.58B | 1.48B | 1.54B | 1.34B | 1.22B | 968.40M | 868.20M | 771.10M | 824.79M | 847.08M | 788.13M | 705.15M | 702.11M | 635.48M | 585.85M | 485.82M | 450.71M | 411.01M |
| Cost & Expenses | 2.49B | 2.29B | 2.12B | 1.97B | 2.03B | 1.79B | 1.61B | 1.32B | 1.21B | 1.08B | 1.08B | 1.10B | 1.04B | 941.35M | 939.91M | 855.41M | 784.88M | 667.19M | 627.55M | 587.32M |
| Interest Income | 18.30M | 500.00K | 2.90M | 2.30M | 2.60M | 3.90M | 1.10M | 1.20M | 1.10M | 1.40M | 1.35M | 1.67M | 1.75M | 2.24M | 2.70M | 21.43M | 11.54M | 2.60M | -1.38M | 0.00 |
| Interest Expense | 37.70M | 18.50M | 23.70M | 27.50M | 31.40M | 10.20M | 11.20M | 7.00M | 3.90M | 5.90M | 4.82M | 5.37M | 1.76M | 1.59M | 4.40M | 4.35M | 13.49M | 2.48M | 6.53M | 0.00 |
| Depreciation & Amortization | 87.90M | 201.30M | 246.40M | 234.70M | 161.20M | 142.60M | 97.90M | 49.10M | 43.70M | 50.20M | 25.75M | 72.56M | 114.69M | 39.39M | 44.94M | 50.65M | 41.23M | 49.94M | 28.87M | 35.02M |
| EBITDA | 887.10M | 1.07B | 1.06B | 794.60M | 153.30M | 646.80M | 487.70M | 343.90M | 284.90M | 262.40M | 232.00M | 198.19M | 148.00M | 166.37M | 216.64M | 246.78M | 258.80M | 237.76M | 190.41M | 161.42M |
| EBITDA Ratio | 26.83% | 38.09% | 36.99% | 35.51% | 31.65% | 29.12% | 24.44% | 23.33% | 23.57% | 22.02% | 17.76% | 19.30% | 22.64% | 22.77% | 19.48% | 23.00% | 26.32% | 28.79% | 24.07% | 22.30% |
| Operating Income | 816.00M | 729.90M | 849.50M | 719.00M | 691.10M | 519.40M | 397.20M | 304.70M | 244.00M | 221.40M | 190.75M | 114.80M | 75.78M | 128.80M | 172.47M | 180.09M | 208.89M | 187.22M | 161.69M | 125.92M |
| Operating Income Ratio | 24.68% | 23.12% | 28.33% | 26.77% | 25.67% | 22.12% | 19.74% | 18.23% | 16.05% | 16.62% | 14.88% | 8.99% | 6.14% | 11.01% | 15.50% | 17.35% | 21.02% | 21.73% | 20.50% | 17.39% |
| Total Other Income/Expenses | -54.50M | -23.80M | -35.50M | 6.30M | -1.40M | -25.40M | -26.50M | -6.90M | -6.70M | -15.10M | -9.00M | 5.45M | -3.94M | -3.41M | -5.16M | 1.07M | -2.03M | -1.54M | -6.68M | -10.28M |
| Income Before Tax | 761.50M | 706.10M | 814.40M | 528.60M | -38.70M | 494.00M | 370.70M | 297.80M | 237.30M | 206.30M | 181.77M | 120.26M | 41.37M | 125.40M | 167.31M | 181.16M | 206.86M | 185.68M | 155.01M | 115.64M |
| Income Before Tax Ratio | 23.03% | 22.37% | 27.15% | 19.68% | -1.44% | 21.04% | 18.43% | 17.82% | 15.61% | 15.48% | 14.18% | 9.41% | 3.35% | 10.71% | 15.04% | 17.45% | 20.82% | 21.55% | 19.65% | 15.97% |
| Income Tax Expense | 136.20M | 112.30M | 168.20M | -17.80M | 19.60M | 108.10M | 101.40M | 73.50M | 49.80M | 53.80M | 39.56M | 24.44M | -13.34M | 16.96M | 10.59M | 33.32M | 54.48M | 40.89M | 32.64M | 40.24M |
| Net Income | 644.40M | 648.60M | 646.60M | 548.00M | -58.30M | 389.50M | 272.30M | 225.90M | 189.90M | 153.50M | 152.54M | -29.49M | 424.00K | 95.68M | 157.17M | 147.67M | 151.07M | 144.01M | 119.23M | 83.00M |
| Net Income Ratio | 19.49% | 20.55% | 21.56% | 20.40% | -2.17% | 16.59% | 13.54% | 13.52% | 12.49% | 11.52% | 11.90% | -2.31% | 0.03% | 8.18% | 14.13% | 14.22% | 15.20% | 16.71% | 15.12% | 11.46% |
| EPS | 7.09 | 1.97 | 1.96 | 1.65 | -0.17 | 1.17 | 0.82 | 0.68 | 0.57 | 0.47 | 0.46 | -0.09 | 0.00 | 0.28 | 0.47 | 0.44 | 0.45 | 0.43 | 0.35 | 0.25 |
| EPS Diluted | 7.40 | 1.95 | 1.94 | 1.64 | -0.17 | 1.17 | 0.82 | 0.68 | 0.57 | 0.47 | 0.46 | -0.09 | 0.00 | 0.28 | 0.47 | 0.44 | 0.45 | 0.43 | 0.35 | 0.25 |
| Weighted Avg Shares Out | 87.08M | 329.66M | 330.59M | 331.86M | 334.03M | 332.99M | 332.12M | 330.49M | 330.81M | 328.88M | 332.65M | 333.84M | 333.86M | 338.05M | 337.21M | 336.06M | 335.89M | 336.86M | 336.10M | 336.10M |
| Weighted Avg Shares Out (Dil) | 83.38M | 332.39M | 333.43M | 333.79M | 334.03M | 332.99M | 332.12M | 330.49M | 330.81M | 328.88M | 332.65M | 333.84M | 333.86M | 338.05M | 337.21M | 336.06M | 335.89M | 336.86M | 336.10M | 336.10M |
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors
2 More Potential Biotech Buyout Targets
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
US FDA approves Ipsen's rare bone disorder drug
US FDA approves Ipsen's SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
Ipsen S.A. publishes its 2023 Half-Year Financial Report
Ipsen S.A. (IPSEY) Q4 2022 Earnings Call Transcript
Ipsen S.A.'s (IPSEY) CEO David Loew on Q2 2022 Results - Earnings Call Transcript
EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM
Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology
Source: https://incomestatements.info
Category: Stock Reports